Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  De Feo, Christopher J ^a   Wang, Wei ^a   Hsieh, Meng Lun ^a,b   Zhuang, Min ^a,c   Vassell, Russell ^a   Weiss, Carol D ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Michigan State University   (United States)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Entry kinetics; Fusion; gp41; HIV entry; Peptide fusion inhibitor; Resistance

Indexed keywords

GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; VIRUS ENVELOPE PROTEIN; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; MULTIPROTEIN COMPLEX; MUTANT PROTEIN;

ANTIVIRAL RESISTANCE; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG POTENCY; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PREDICTION; PROTEIN DOMAIN; PROTEIN STABILITY; THERMODYNAMICS; VIRUS ENTRY; VIRUS INFECTIVITY; CELL LINE; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; KINETICS; METABOLISM; PHYSIOLOGY; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION;

CELL LINE; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; KINETICS; MULTIPROTEIN COMPLEXES; MUTANT PROTEINS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; THERMODYNAMICS; VIRUS INTERNALIZATION;

EID: 84908069690     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-014-0086-8     Document Type: Article

References (65)

1. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001, 70:777-810. 10.1146/annurev.biochem.70.1.777, 11395423.
2. Melikyan GB. Membrane fusion mediated by human immunodeficiency virus envelope glycoprotein. Curr Top Membr 2011, 68:81-106. 10.1016/B978-0-12-385891-7.00004-0, 21771496.
3. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawat SS, Puri A, Durell S, Blumenthal R. The HIV Env-mediated fusion reaction. Biochim Biophys Acta 2003, 1614(1):36-50. 10.1016/S0005-2736(03)00161-5, 12873764.
4. De Feo CJ, Weiss CD. Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors. Viruses 2012, 4(12):3859-3911. 10.3390/v4123859, 23342377.
5. Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010, 22(3):358-366. 10.1016/j.coi.2010.02.012, 20299194.
6. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998, 4(11):1302-1307. 10.1038/3293, 9809555.
7. Wild C, Greenwell T, Shugars D, Rimsky-Clarke L, Matthews T. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res Hum Retroviruses 1995, 11(3):323-325. 10.1089/aid.1995.11.323, 7786578.
8. Chen CH, Matthews TJ, McDanal CB, Bolognesi DP, Greenberg ML. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol 1995, 69(6):3771-3777. 7538176.
9. Tan K, Liu J, Wang J, Shen S, Lu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 1997, 94(23):12303-12308. 10.1073/pnas.94.23.12303, 9356444.
10. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387(6631):426-430. 10.1038/387426a0, 9163431.
11. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998, 93(5):681-684. 10.1016/S0092-8674(00)81430-0, 9630213.
12. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89(2):263-273. 10.1016/S0092-8674(00)80205-6, 9108481.
13. He Y, Vassell R, Zaitseva M, Nguyen N, Yang Z, Weng Y, Weiss CD. Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 2003, 77(3):1666-1671. 10.1128/JVI.77.3.1666-1671.2003, 12525600.
14. Kilgore NR, Salzwedel K, Reddick M, Allaway GP, Wild CT. Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J Virol 2003, 77(13):7669-7672. 10.1128/JVI.77.13.7669-7672.2003, 12805467.
15. Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A 1998, 95(26):15613-15617. 10.1073/pnas.95.26.15613, 9861018.
16. Furuta RA, Wild CT, Weng Y, Weiss CD. Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 1998, 5(4):276-279. 10.1038/nsb0498-276, 9546217.
17. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003, 348(22):2175-2185. 10.1056/NEJMoa035026, 12637625.
18. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994, 91(21):9770-9774. 10.1073/pnas.91.21.9770, 7937889.
19. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004, 54(2):333-340. 10.1093/jac/dkh330, 15231762.
20. Lu J, Deeks SG, Hoh R, Beatty G, Kuritzkes BA, Martin JN, Kuritzkes DR. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 2006, 43(1):60-64. 10.1097/01.qai.0000234083.34161.55, 16885776.
21. Sista PR, Melby T, Davison D, Jin L, Mosier S, Mink M, Nelson EL, DeMasi R, Cammack N, Salgo MP, Matthews TJ, Greenberg ML. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004, 18(13):1787-1794. 10.1097/00002030-200409030-00007, 15316339.
22. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004, 3(3):215-225. 10.1038/nrd1331, 15031735.
23. Baldwin CE, Sanders RW, Deng Y, Jurriaans S, Lange JM, Lu M, Berkhout B. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol 2004, 78(22):12428-12437. 10.1128/JVI.78.22.12428-12437.2004, 15507629.
24. Cai L, Jiang S. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. ChemMedChem 2010, 5(11):1813-1824. 10.1002/cmdc.201000289, 20845360.
25. Yu X, Lu L, Cai L, Tong P, Tan S, Zou P, Meng F, Chen YH, Jiang S. Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket. J Virol 2012, 86(1):589-593. 10.1128/JVI.05066-11, 22013063.
26. Eggink D, Bontjer I, Langedijk JP, Berkhout B, Sanders RW. Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J Virol 2011, 85(20):10785-10797. 10.1128/JVI.05331-11, 21835789.
27. Hermann FG, Egerer L, Brauer F, Gerum C, Schwalbe H, Dietrich U, Von Laer D. Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46. J Virol 2009, 83(10):4844-4853. 10.1128/JVI.00666-08, 19279116.
28. Lohrengel S, Hermann F, Hagmann I, Oberwinkler H, Scrivano L, Hoffmann C, von Laer D, Dittmar MT. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J Virol 2005, 79(16):10237-10246. 10.1128/JVI.79.16.10237-10246.2005, 16051817.
29. Liu Z, Shan M, Li L, Lu L, Meng S, Chen C, He Y, Jiang S, Zhang L. In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2011, 286(5):3277-3287. 10.1074/jbc.M110.199323, 21098485.
30. Shimura K, Nameki D, Kajiwara K, Watanabe K, Sakagami Y, Oishi S, Fujii N, Matsuoka M, Sarafianos SG, Kodama EN. Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors. J Biol Chem 2010, 285(50):39471-39480. 10.1074/jbc.M110.145789, 20937812.
31. Eggink D, Baldwin CE, Deng Y, Langedijk JP, Lu M, Sanders RW, Berkhout B. Selection of T1249-resistant human immunodeficiency virus type 1 variants. J Virol 2008, 82(13):6678-6688. 10.1128/JVI.00352-08, 18434391.
32. Berkhout B, Eggink D, Sanders RW. Is there a future for antiviral fusion inhibitors?. Curr Opin Virol 2012, 2(1):50-59. 10.1016/j.coviro.2012.01.002, 22440966.
33. Eggink D, Berkhout B, Sanders RW. Inhibition of HIV-1 by fusion inhibitors. Curr Pharm Des 2010, 16(33):3716-3728. 10.2174/138161210794079218, 21128887.
34. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998, 72(2):986-993. 9444991.
35. Poveda E, Rodes B, Lebel-Binay S, Faudon JL, Jimenez V, Soriano V. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J Clin Virol 2005, 34(4):295-301. 10.1016/j.jcv.2005.02.004, 16286053.
36. Eggink D, Langedijk JP, Bonvin AM, Deng Y, Lu M, Berkhout B, Sanders RW. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J Biol Chem 2009, 284(39):26941-26950. 10.1074/jbc.M109.004416, 19617355.
37. Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 2005, 79(19):12447-12454. 10.1128/JVI.79.19.12447-12454.2005, 16160172.
38. Nameki D, Kodama E, Ikeuchi M, Mabuchi N, Otaka A, Tamamura H, Ohno M, Fujii N, Matsuoka M. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J Virol 2005, 79(2):764-770. 10.1128/JVI.79.2.764-770.2005, 15613304.
39. Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 2004, 48(9):3253-3259. 10.1128/AAC.48.9.3253-3259.2004, 15328081.
40. Ray N, Blackburn LA, Doms RW. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J Virol 2009, 83(7):2989-2995. 10.1128/JVI.02496-08, 19153234.
41. Tolstrup M, Selzer-Plon J, Laursen AL, Bertelsen L, Gerstoft J, Duch M, Pedersen FS, Ostergaard L. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K). AIDS 2007, 21(4):519-521. 10.1097/QAD.0b013e3280187558, 17301572.
42. Bai X, Wilson KL, Seedorff JE, Ahrens D, Green J, Davison DK, Jin L, Stanfield-Oakley SA, Mosier SM, Melby TE, Cammack N, Wang Z, Greenberg ML, Dwyer JJ. Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure. Biochemistry 2008, 47(25):6662-6670. 10.1021/bi702509d, 18507398.
43. Xu L, Pozniak A, Wildfire A, Stanfield-Oakley SA, Mosier SM, Ratcliffe D, Workman J, Joall A, Myers R, Smit E, Cane PA, Greenberg ML, Pillay D. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005, 49(3):1113-1119. 10.1128/AAC.49.3.1113-1119.2005, 15728911.
44. Bewley CA, Louis JM, Ghirlando R, Clore GM. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem 2002, 277(16):14238-14245. 10.1074/jbc.M201453200, 11859089.
45. Root MJ, Kay MS, Kim PS. Protein design of an HIV-1 entry inhibitor. Science 2001, 291(5505):884-888. 10.1126/science.1057453, 11229405.
46. Zhuang M, Wang W, De Feo CJ, Vassell R, Weiss CD. Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways. J Biol Chem 2012, 287(11):8297-8309. 10.1074/jbc.M111.324483, 22235115.
47. Desmezieres E, Gupta N, Vassell R, He Y, Peden K, Sirota L, Yang Z, Wingfield P, Weiss CD. Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120. J Virol 2005, 79(8):4774-4781. 10.1128/JVI.79.8.4774-4781.2005, 15795263.
48. Wang W, De Feo CJ, Zhuang M, Vassell R, Weiss CD. Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41. J Virol 2011, 85(24):12929-12938. 10.1128/JVI.05391-11, 21994458.
49. Izumi K, Nakamura S, Nakano H, Shimura K, Sakagami Y, Oishi S, Uchiyama S, Ohkubo T, Kobayashi Y, Fujii N, Matsuoka M, Kodama EN. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat. Antiviral Res 2010, 87(2):179-186. 10.1016/j.antiviral.2010.04.011, 20438763.
50. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A 2002, 99(25):16249-16254. 10.1073/pnas.252469399, 12444251.
51. Gallo SA, Puri A, Blumenthal R. HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process. Biochemistry 2001, 40(41):12231-12236. 10.1021/bi0155596, 11591141.
52. Abrahamyan LG, Mkrtchyan SR, Binley J, Lu M, Melikyan GB, Cohen FS. The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. J Virol 2005, 79(1):106-115. 10.1128/JVI.79.1.106-115.2005, 15596806.
53. Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 2005, 79(8):4991-4999. 10.1128/JVI.79.8.4991-4999.2005, 15795284.
54. Eckert DM, Kim PS. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci U S A 2001, 98(20):11187-11192. 10.1073/pnas.201392898, 11572974.
55. Cavrois M, De Noronha C, Greene WC. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol 2002, 20(11):1151-1154. 10.1038/nbt745, 12355096.
56. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009, 137(3):433-444. 10.1016/j.cell.2009.02.046, 19410541.
57. Putcharoen O, Lee SH, Henrich TJ, Hu Z, Vanichanan J, Coakley E, Greaves W, Gulick RM, Kuritzkes DR, Tsibris AM. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. J Virol 2012, 86(2):1119-1128. 10.1128/JVI.06421-11, 22090117.
58. Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure AL, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DR. Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures. J Virol 2012, 86(12):6416-6426. 10.1128/JVI.00286-12, 22491471.
59. Louis JM, Bewley CA, Clore GM. Design and properties of N (CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem 2001, 276(31):29485-29489. 10.1074/jbc.C100317200, 11418583.
60. Kahle KM, Steger HK, Root MJ. Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog 2009, 5(11):e1000674. 10.1371/journal.ppat.1000674, 19956769.
61. Miyauchi K, Kozlov MM, Melikyan GB. Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation. PLoS Pathog 2009, 5(9):e1000585. 10.1371/journal.ppat.1000585, 19763181.
62. Bartesaghi A, Merk A, Borgnia MJ, Milne JL, Subramaniam S. Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat Struct Mol Biol 2013, 20(12):1352-1357. 10.1038/nsmb.2711, 24154805.
63. Mao Y, Wang L, Gu C, Herschhorn A, Xiang SH, Haim H, Yang X, Sodroski J. Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat Struct Mol Biol 2012, 19(9):893-899. 10.1038/nsmb.2351, 22864288.
64. Lyumkis D, Julien JP, De Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342(6165):1484-1490. 10.1126/science.1245627, 24179160.
65. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342(6165):1477-1483. 10.1126/science.1245625, 24179159.